Study guide
8.2 Multimodal Analgesia: Opioids, Ketamine, Gabapentinoids, NSAIDs, and Regional Anesthesia
Certified Burn Registered Nurse CBRN
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction & Foundations of Burn Care
1.1 CBRN Exam Format, Eligibility, and BCEN Testing Standards 1.2 Anatomy, Histology, and Barrier Functions of the Skin 1.3 Burn Depth Classification and Jackson's Thermal Wound Zones
2 Chapter 2: Pathophysiology of Burn Injury & Systemic Response
2.1 Cellular Pathophysiology and Capillary Permeability in Burn Shock 2.2 Systemic Inflammatory Response Syndrome (SIRS) and MODS 2.3 Pathophysiology of Supraglottic, Subglottic, and Inhalational Injury 2.4 Cellular Phases of Burn Wound Healing and Scar Pathobiology
3 Chapter 3: Prehospital Triage, Primary Survey & Transfer Criteria
3.1 Initial Assessment, Primary Survey (ABCDEF), and Field Stabilization 3.2 Total Body Surface Area (TBSA) Calculation: Rule of Nines, Lund-Browder, and Palmar Method 3.3 American Burn Association (ABA) Burn Center Referral Criteria and Transport Logistics
4 Chapter 4: Fluid Resuscitation & Hemodynamic Stabilization (<72 Hours)
4.1 Fluid Resuscitation Formulas: Parkland (Baxter), Modified Brooke, and Consensus Protocols 4.2 Resuscitation Endpoints: Urine Output Titration, Base Deficit, and Hemodynamic Monitoring 4.3 Complications of Fluid Creep and Intra-Abdominal Hypertension / Abdominal Compartment Syndrome 4.4 Extremity Compartment Syndrome, Monitoring, and Emergent Escharotomy / Fasciotomy
5 Chapter 5: Airway Management & Inhalation Injury Management
5.1 Upper Airway Compromise, Indications for Early Endotracheal Intubation, and Airway Stabilization 5.2 Lower Airway Chemical Tracheobronchitis, Diagnostic Bronchoscopy, and Lung-Protective Mechanical Ventilation 5.3 Carbon Monoxide (CO) Toxicity, Cyanide Poisoning, and Specific Antidotes (Hydroxocobalamin)
6 Chapter 6: Acute Multisystem Assessment & Critical Care Management
6.1 Cardiovascular Derangements, Myocardial Depression, and Hemodynamic Optimization 6.2 Acute Kidney Injury, Rhabdomyolysis / Myoglobinuria, and Fluid-Electrolyte Shifts 6.3 Gastrointestinal Complications, Ileus, Early Enteral Nutrition, and Curling's Ulcer Prophylaxis 6.4 Neurological Impairment, Anemia of Burn Injury, Coagulopathy, and Musculoskeletal Protection
7 Chapter 7: Hypermetabolism & Nutritional Support
7.1 The Biphasic Metabolic Response: Ebb vs. Flow Phases and Persistent Hypermetabolism 7.2 Indirect Calorimetry, Caloric Equations (Curreri/Toronto), and Micronutrient / Trace Mineral Needs 7.3 Pharmacological Modulation: Propranolol, Oxandrolone, Growth Hormone, and Exercise Therapy 7.4 Stress Hyperglycemia, Intensive Insulin Protocols, and Adrenal / Thyroid Axis Dysregulation
8 Chapter 8: Pain Management in Burn Care
8.1 Pain Classification in Burns: Background, Procedural, Breakthrough, and Chronic Neuropathic Pain 8.2 Multimodal Analgesia: Opioids, Ketamine, Gabapentinoids, NSAIDs, and Regional Anesthesia 8.3 Non-Pharmacological Modalities: Virtual Reality, Cognitive Behavioral Techniques, Hypnosis, and Distraction
9 Chapter 9: Agitation, Delirium & Post-Burn Pruritus
9.1 Agitation Management, Targeted Sedation Protocols (RASS/SAS), and Circadian Rhythm Support 9.2 ICU Delirium: Risk Factors, Screening (CAM-ICU/ICDSC), Non-Pharmacological Bundles, and Medical Management 9.3 Post-Burn Itch: Histaminergic vs. Neuropathic Pruritus, Oral Antihistamines, Gabapentin, and Topical Emollients
10 Chapter 10: Burn Wound Assessment, Topical Antimicrobials & Dressings
10.1 Serial Wound Bed Assessment, Tissue Perfusion, and Documentation Standards 10.2 Topical Antimicrobial Formulations: Silver Sulfadiazine, Mafenide Acetate, Silver Nitrate, and Modern Silver Dressings 10.3 Wound Bed Preparation: Surgical, Enzymatic (Collagenase/Bromelain), Autolytic, and Mechanical Debridement 10.4 Modern Dressings, Hydrogels, Foam Dressings, Negative Pressure Wound Therapy (NPWT), and Moisture Retentive Balances
11 Chapter 11: Surgical Excision, Skin Grafting & Wound Closure
11.1 Principles of Early Tangential vs. Fascial Surgical Excision and Blood Conservation 11.2 Split-Thickness and Full-Thickness Autografting: Mesh Expansion Ratios vs. Sheet Grafts 11.3 Biologic Coverings, Dermal Regeneration Templates (Integra/Novosorb BTM), Allograft, and Xenograft 11.4 Autologous Cell Suspensions (ReCell), Cultured Epithelial Autografts (CEA), and Donor Site Management
12 Chapter 12: Burn Sepsis, Infection Control & Antimicrobial Therapy
12.1 Burn Center Infection Control: Contact Precautions, Hydrotherapy Sanitation, and Environmental Controls 12.2 Differentiating Hypermetabolic SIRS from Burn Sepsis: ABA Consensus Sepsis Criteria 12.3 Common Burn Pathogens (Pseudomonas, MRSA, Acinetobacter, Candida, Aspergillus) and Empiric Coverage 12.4 Invasive Burn Wound Infection: Clinical Signs, Quantitative Biopsy (>10^5 CFU/g), and Histopathological Invasion
13 Chapter 13: Specific Burn Etiologies: Electrical, Chemical & Cold Injuries
13.1 Electrical Burn Injuries: High-Voltage vs. Low-Voltage, Arc/Flash, Cardiac Monitoring, and Deep Muscle Necrosis 13.2 Chemical Injuries: Acids (Coagulation Necrosis), Alkalis (Liquefactive Necrosis), Hydrofluoric Acid (Calcium Gluconate), and Decontamination 13.3 Radiation Burns, Cutaneous Radiation Syndrome, Cold Injuries (Frostbite Triage and Thawing Protocols), and Vasodilator Therapy
14 Chapter 14: Special Burn Populations & Cutaneous Syndromes
14.1 Pediatric Burn Resuscitation (Maintenance Fluids + D5W), Surface Area Dynamics, and Non-Accidental Trauma Screening 14.2 Geriatric Burn Care: Thin Dermis, Altered Fluid Tolerance, Pre-existing Comorbidities, and Mortality Prognostication (Baux Score) 14.3 Burn Injury in Pregnancy: Maternal Physiology, Resuscitation, and Fetal Surveillance 14.4 Severe Cutaneous Adverse Reactions: Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), SCORTEN, and Specialized Burn Unit Nursing 14.5 Necrotizing Soft Tissue Infections and Friction/Shear Injuries
15 Chapter 15: Rehabilitation, Scar Management & Reconstruction
15.1 Anti-Deformity Positioning, Range-of-Motion Exercises, and Custom Splinting Across Major Joints 15.2 Hypertrophic Scarring Mechanisms, Myofibroblasts, and Vancouver Scar Scale (VSS) Assessment 15.3 Custom Pressure Garments (20-30 mmHg), Silicone Sheeting, Fractional CO2 Laser Resurfacing, and Contracture Release 15.4 Psychosocial Recovery, Post-Traumatic Stress Disorder (PTSD), Body Image Adaptation, Peer Support (Phoenix Society), and School/Work Reintegration 15.5 Discharge Teaching, Transition to Ambulatory Care, and Home Management
16 Chapter 16: Professional Practice, Ethics, Quality & Disaster Triage
16.1 Ethical Dilemmas in Burn Critical Care, Surrogate Decision-Making, Futility, and Palliative / End-of-Life Symptom Management 16.2 Interprofessional Burn Team Roles, Multidisciplinary Rounds, Structured Handoffs, and Patient/Family Advocacy 16.3 Burn Quality Improvement, American Burn Association (ABA) Verification Standards, and National Burn Repository (NBR) Benchmarking 16.4 Diversity, Equity, Inclusion, and Intraprofessional Nursing Development 16.5 Community Outreach, Burn Prevention Education, and Home Safety 16.6 Mass Casualty Burn Disasters, Secondary Triage Schemes (ABA/ABLS Triage Matrix), Surge Capacity, and CBRN/HAZMAT Emergency Response
8.2 Multimodal Analgesia: Opioids, Ketamine, Gabapentinoids, NSAIDs, and Regional Anesthesia
Key Takeaways Explain This Topic AI
The American Burn Association (ABA) multimodal analgesia paradigm targets distinct neurochemical pain pathways simultaneously, maximizing analgesic synergy while minimizing opioid dosages and adverse effects (ileus, respiratory depression, sedation, tolerance, and opioid-induced hyperalgesia).
Opioid analgesia serves as the bedrock of acute burn pain management; fentanyl is optimal for rapid-onset procedural analgesia, hydromorphone is preferred in renal impairment, and methadone uniquely combines mu-opioid agonism with NMDA antagonism for refractory neuropathic pain and opioid-tolerant individuals.
Sub-anesthetic ketamine (0.1–0.5 mg/kg IV bolus or 0.1–0.2 mg/kg/hr infusion) acts as a non-competitive NMDA receptor antagonist, effectively preventing and reversing central sensitization, dorsal horn wind-up, and opioid-induced hyperalgesia while preserving spontaneous respiration.
Gabapentinoids (gabapentin and pregabalin) modulate presynaptic voltage-gated calcium channels to suppress excitatory neurotransmitter release (glutamate, substance P), serving as first-line agents for post-burn neuropathic pain and pruritus.
Non-opioid adjuncts (scheduled acetaminophen, judicious NSAIDs, dexmedetomidine/clonidine) and regional nerve blocks (fascia iliaca, femoral, TAP blocks) significantly reduce opioid requirements and facilitate early burn rehabilitation.
Last updated: August 2026
8.2 Multimodal Analgesia: Opioids, Ketamine, Gabapentinoids, NSAIDs, and Regional Anesthesia
Core Knowledge: Managing severe thermal injury pain solely with escalating doses of opioid monotherapy is obsolete, ineffective, and clinically hazardous. High-dose opioid monotherapy inevitably leads to rapid pharmacological tolerance, bowel hypomotility / paralytic ileus, severe sedation, respiratory depression, and Opioid-Induced Hyperalgesia (OIH) . In alignment with American Burn Association (ABA) Clinical Practice Guidelines , the standard of care is a structured multimodal analgesia paradigm that combines pharmacological agents with complementary mechanisms of action acting across different anatomical and neurochemical pathways.
1. The Multimodal Analgesia Paradigm in Thermal Injury
Multimodal analgesia achieves pharmacological synergy: by combining lower doses of diverse analgesic classes, clinicians optimize pain relief across all four neurobiological stages of nociception while significantly blunting drug-specific adverse effects. MULTIMODAL PHARMACOLOGICAL TARGETS
- ┌────────────────────────────────────────────────────────────────────────┐
- │ [1] TRANSDUCTION (Peripheral Nociceptor Activation) │
- │ • NSAIDs & Acetaminophen ──► Inhibit Cyclooxygenase (COX-1/COX-2) │
- │ • Topical Lidocaine ───────► Blocks Voltage-Gated Na+ Channels │
- ├────────────────────────────────────────────────────────────────────────┤
- │ [2] TRANSMISSION (Peripheral Nerve to Dorsal Horn) │
- │ • Regional Nerve Blocks ───► Local anesthetics halt action pot. │
- │ • Gabapentinoids ──────────► Block α2δ Subunit of Presynaptic Ca2+ │
- ├────────────────────────────────────────────────────────────────────────┤
- │ [3] MODULATION (Dorsal Horn Spinal Processing & Wind-Up) │
- │ • Ketamine & Methadone ────► NMDA Receptor Antagonism (Anti-Windup)│
- │ • Alpha-2 Agonists ────────► Precedex / Clonidine augment descending│
- │ inhibitory noradrenergic pathways │
- ├────────────────────────────────────────────────────────────────────────┤
- │ [4] PERCEPTION (Thalamic, Limbic & Somatosensory Cortical Processing) │
- │ • Opioids (Fentanyl/Morph) ─► Mu (μ) Opioid Receptor Agonism │
- │ • Dexmedetomidine ─────────► Locus coeruleus sedative-analgesia │
- └────────────────────────────────────────────────────────────────────────┘
- 2. Opioid Analgesics in Burn Care
Opioids remain the cornerstone of acute burn analgesia for severe background and procedural pain. However, pharmacokinetic profiles dictate distinct clinical applications.
Opioid Agent Route & Typical Adult Dosing Onset / Peak / Duration Key Pharmacokinetic & Clinical Nuances
Fentanyl IV: 25–100 mcg bolus (0.5–2 mcg/kg); Transmucosal/Nasal: 100–400 mcg Onset: 1–2 min; Peak: 3–5 min; Duration: 30–60 min Highly lipophilic synthetic opioid with rapid onset; ideal for acute procedural pain (dressing changes, hydrotherapy). Minimal histamine release; hemodynamically stable. Rapid redistribution causes short duration.
Morphine IV: 2–10 mg q2–4h; Oral: 15–30 mg q3–4h Onset: 5–10 min; Peak: 15–30 min; Duration: 3–4 hours Cleared renally; active metabolites Morphine-6-glucuronide (M6G) (potent analgesic) and Morphine-3-glucuronide (M3G) (neurotoxic: induces hyperalgesia, allodynia, myoclonus). Triggers histamine release causing peripheral vasodilation, hypotension, and pruritus.
Hydromorphone (Dilaudid) IV: 0.5–2 mg q2–3h; Oral: 2–4 mg q3–4h Onset: 2–5 min; Peak: 10–20 min; Duration: 2–3 hours 5 to 7 times more potent than IV morphine . Lacks toxic glucuronide metabolites; preferred first-line opioid in renal insufficiency or acute kidney injury (AKI) . Lower incidence of histamine-induced pruritus and sedation compared to morphine.
Methadone Oral/IV: 2.5–10 mg q8–12h (carefully individualized) Onset: 15–30 min; Peak: 1–2 hours; Duration: 8–12+ hours Unique triple mechanism: Mu-opioid agonist , potent NMDA receptor antagonist , and serotonin/norepinephrine reuptake inhibitor . Outstanding for severe neuropathic pain, opioid-tolerant patients, and mitigating OIH. Complex elimination half-life (15–60 hours) requires cautious titration and baseline/serial ECG monitoring for QTc prolongation (risk of Torsades de Pointes).
Patient-Controlled Analgesia (PCA) Rules & Safety Benchmarks
Patient-Controlled Analgesia empowers communicative, cognitively intact burn patients to titrate intravenous analgesia directly to their comfort level:
Demand (Bolus) Dose: Standard prescribed aliquot (e.g., Hydromorphone 0.2–0.4 mg or Morphine 1–2 mg) delivered upon button press.
Lockout Interval: Programmed refractory window (typically 6 to 10 minutes ) preventing delivery of another dose until the previous dose reaches peak clinical effect, preventing stacking and inadvertent overdose.
Continuous Basal Rate Controversy: Continuous basal infusions on PCA pumps in opioid-naive patients significantly increase the risk of nocturnal hypoventilation, severe respiratory depression, and fatal overdose. Basal rates should be restricted to opioid-tolerant burn patients with documented high resting background pain.
Monitoring Standards: Continuous pulse oximetry and end-tidal capnography ( E t C O 2 EtCO_2 EtC O 2 ) are mandatory for patients receiving continuous basal PCA or high-dose opioid regimens to detect early hypoventilation prior to pulse oximetry desaturation.
"PCA by Proxy" Prohibition: Family members, visitors, and bedside staff are strictly prohibited from pressing the PCA button on behalf of a sleeping or sedated patient. The patient's own waking state and cognitive drive serve as the primary physiological safety barrier against fatal overdose.
3. Sub-Anesthetic Ketamine: NMDA Receptor Blockade
Ketamine is a phencyclidine (PCP) derivative that has revolutionized burn pain management. At sub-anesthetic dosages ( 0.1 to 0.5 mg/kg IV bolus or 0.1 to 0.2 mg/kg/hr continuous infusion ), ketamine functions as a potent analgesic and anti-hyperalgesic agent rather than a general anesthetic. KETAMINE MECHANISM & CLINICAL UTILITY
- ┌────────────────────────────────────────────────────────────────────────┐
- │ NON-COMPETITIVE NMDA ANTAGONISM │
- ├────────────────────────────────────────────────────────────────────────┤
- │ • Binds the phencyclidine site inside the open NMDA receptor channel │
- │ • Blocks calcium influx into dorsal horn Wide Dynamic Range neurons │
- │ • Halts spinal "Wind-Up" and reverses central sensitization │
- │ • PREVENTS & REVERSES Opioid-Induced Hyperalgesia (OIH) │
- ├────────────────────────────────────────────────────────────────────────┤
- │ UNIQUE PHYSIOLOGICAL ADVANTAGES │
- ├────────────────────────────────────────────────────────────────────────┤
- │ • Preserves pharyngeal/laryngeal protective airway reflexes │
- │ • Maintains spontaneous minute ventilation (minimal respiratory depr.)│
- │ • Bronchodilation (beneficial in smoke inhalation / reactive airway) │
- │ • Sympathomimetic release of catecholamines (supports BP & HR) │
- ├────────────────────────────────────────────────────────────────────────┤
- │ MANAGEMENT OF PSYCHOMIMETIC EFFECTS │
- ├────────────────────────────────────────────────────────────────────────┤
- │ • Emergence reactions, vivid dreams, hallucinations, and dysphoria │
- │ • Mitigated by co-administering low-dose Midazolam (1–2 mg IV) or │
- │ Dexmedetomidine (Precedex) │
- └────────────────────────────────────────────────────────────────────────┘
- Opioid-Induced Hyperalgesia (OIH) vs. Pharmacological Tolerance
A critical diagnostic competency for the CBRN is differentiating Opioid-Induced Hyperalgesia (OIH) from Opioid Tolerance in burn patients receiving escalating opioid doses:
Tolerance: Characterized by a rightward shift of the dose-response curve; increasing the opioid dose successfully restores analgesic efficacy.
Opioid-Induced Hyperalgesia (OIH): A paradoxical state wherein escalating opioid administration actually worsens pain sensitivity, expanding allodynia and hyperalgesia to unburned anatomical regions. Driven by neurotoxic opioid metabolites (such as morphine-3-glucuronide) and massive spinal NMDA receptor activation. Increasing the opioid dose worsens the pain . The definitive treatment is adding sub-anesthetic ketamine or transitioning to methadone to block NMDA channels, while reducing the total opioid burden.
4. Gabapentinoids and Membrane Stabilizers
Neuropathic pain, graft donor site dysesthesias, and debilitating post-burn pruritus are mediated by damaged cutaneous nerve terminals. Gabapentinoids (Gabapentin and Pregabalin) are foundational first-line agents in the ABA multimodal bundle:
Mechanism of Action: Selectively bind to the α 2 δ − 1 \alpha_2\delta-1 α 2 δ − 1 auxiliary subunit of presynaptic voltage-gated calcium channels in the dorsal horn and brain. This binding blocks calcium influx, dramatically reducing the exocytotic release of excitatory neurotransmitters ( glutamate, substance P, CGRP, and norepinephrine ).
Clinical Indications: First-line for post-burn neuropathic pain, shooting/electric sensations during scar maturation, deep donor site aching, and neuropathic post-burn pruritus. Demonstrates profound opioid-sparing efficacy (often reducing total daily morphine milligram equivalents [MME] by 30% to 50%).
Dosing & Titration: Gabapentin is initiated at 100–300 mg PO three times daily and titrated upward (maximum 3,600 mg/day). Pregabalin is dosed at 50–150 mg PO twice or three times daily (maximum 600 mg/day).
Critical Nursing Precaution: Gabapentinoids are cleared almost 100% unchanged by the kidneys. In burn patients with acute kidney injury (AKI) or fluctuating creatinine clearance, strict dosage reductions are mandatory to prevent neurotoxicity, profound somnolence, myoclonus, and respiratory depression when combined with opioids.
- 5. Non-Opioid Adjuncts, Alpha-2 Agonists, and Regional Anesthesia
- Non-Opioid Adjuncts
Acetaminophen (IV / Oral): Inhibits central prostaglandin synthesis through COX-3 / peroxidase enzyme inhibition and activates descending serotonergic inhibitory pathways. Administered as a scheduled baseline non-opioid (1,000 mg IV/PO q6h; maximum 4,000 mg/24h in normal adults; restricted to ≤ 2 , 000 – 3 , 000 mg/day \le 2,000\text{–}3,000\text{ mg/day} ≤ 2 , 000 – 3 , 000 mg/day in patients with hepatic dysfunction, chronic alcohol abuse, or severe malnutrition).
NSAIDs (Ketorolac, Ibuprofen, Celecoxib): Block peripheral cyclooxygenase (COX-1 and COX-2) enzymes, reducing inflammatory prostaglandin synthesis and tissue edema. High Caution in Acute Resuscitation: NSAIDs are strictly contraindicated during the initial 48-hour resuscitation phase and in unstable burn shock due to the high risk of compounding acute renal tubular hypoperfusion (blocking compensatory renal prostacyclin vasodilation), triggering GI bleeding / Curling's ulcers, and inducing platelet dysfunction prior to surgical excision.
Alpha-2 Adrenergic Agonists (Dexmedetomidine & Clonidine):
Dexmedetomidine (Precedex): Highly selective central α 2 \alpha_2 α 2 agonist acting on the locus coeruleus. Provides "cooperative sedation" where patients remain easily arousable, anxiolysis, and significant opioid-sparing analgesia without causing respiratory depression . Ideal for mechanically ventilated burn patients, agitated delirium, and procedural dressing changes. Requires continuous monitoring for bradycardia and hypotension.
Clonidine: Oral α 2 \alpha_2 α 2 agonist valuable for mitigating autonomic storming, treating neuropathic background pain, and managing opioid weaning in prolonged ICU stays.
Regional Anesthesia and Peripheral Nerve Blocks
Targeted peripheral nerve blocks deliver dense, localized anesthesia directly to surgical and donor sites, eliminating systemic side effects:
Fascia Iliaca Compartment Block (FICB) & Femoral Nerve Block: Infiltrates local anesthetic (e.g., ropivacaine, bupivacaine) beneath the fascia iliaca, bathing the femoral, lateral femoral cutaneous, and obturator nerves. Serves as the gold standard for anterior/lateral thigh split-thickness skin graft (STSG) donor site harvesting , providing 12 to 24 hours of near-complete site-specific analgesia.
Transversus Abdominis Plane (TAP) Block: Deposits local anesthetic in the fascial plane between the internal oblique and transversus abdominis muscles, providing profound analgesia for trunk/abdominal burn excision or donor harvesting.
Continuous Peripheral Nerve Catheters: Perineural infusion of dilute local anesthetics delivers days of targeted analgesia, dramatically reducing systemic opioid consumption and facilitating aggressive physical therapy joint mobilization.